HyperbilirubinemiaNCT07409194
The Effect of Acupressure on Hyperbilirubinemia in Newborns: A Randomized Controlled Trial
A study testing Acupressure in people with Hyperbilirubinemia, run by Yuzuncu Yil University at 1 site in Turkey (Türkiye).
Trial summary
This study is a randomized controlled trial conducted to evaluate the effect of acupressure application on hyperbilirubinemia in newborns. The study examined the effect of regular acupressure applications to specific points on serum bilirubin levels in newborns at risk of developing physiological jaundice in the first… Read more about this study
- Who is it for?
- Ages 38 weeks to 42 months
- Conditions the study is for
- Hyperbilirubinemia
- What is being tested?
- Acupressure
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 5 May 2025to 15 May 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 38 weeks to 42 months
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Gestational age ≥38 weeks
- Diagnosed with neonatal hyperbilirubinemia
- Hospitalized in the neonatal unit for at least 24 hours
- Birth weight ≥2500 g
- Written informed consent obtained from parents
Who cannot join
- Preterm newborns
- Congenital metabolic disease or congenital anomalies
- Hemodynamically unstable newborns
- Newborns whose parents did not provide consent
- Newborns with any condition preventing acupressure application
Trial locations and contacts
1 site in 1 country.
About this study
This study is a randomized controlled trial conducted to evaluate the effect of acupressure application on hyperbilirubinemia in newborns. The study examined the effect of regular acupressure applications to specific points on serum bilirubin levels in newborns at risk of developing physiological jaundice in the first days of life. By comparing bilirubin levels between the experimental and control groups, the potential benefits of acupressure in reducing the severity of jaundice and supporting bilirubin metabolism were investigated. The findings suggest that acupressure can be used as a complementary method in neonatal care.
Read the detailed description
One of the most common problems encountered in the neonatal period is neonatal jaundice, which develops due to an increase in indirect bilirubin (Özdemir and Yılmaz, 2019). Jaundice (hyperbilirubinemia) is defined as the yellowing of the skin and the whites of the eyes due to the accumulation of bilirubin in the skin and mucous membranes of newborns (Kılıç and Yılmaz, 2021). Jaundice is a common condition seen in 60% of term infants and more than 80% of preterm infants (Muniyappa and Kelley, 2020). Hyperbilirubinemia (HB), which is frequently seen in newborns, especially in the indirect form, is a mild health problem in most cases (Olcar, 2019; Yılmaz, 2019). HB in newborns usually progresses cephalocaudally (from head to toe); it starts in the face and spreads to the body as serum bilirubin levels increase (Turkish Neonatology Association [TND], 2022). Symptoms such as lethargy and feeding difficulties may occur in infants with severe HB. If not treated promptly, serious neurological complications such as kernicterus may occur. Early diagnosis, close monitoring, and treatment are vital to prevent potential damage in newborns (Muniyappa and Kelley, 2020).
Various treatment methods have been developed to reduce bilirubin levels. Among these methods, the most commonly used are blood exchange, phototherapy, and drug treatments (Garg et al., 2019; Kılıç and Yılmaz, 2021). To support neonatal HB treatment, studies evaluating the effectiveness of non-pharmacological and complementary applications, in addition to pharmacological methods, have also been conducted (Öztürk, 2025; Coşkun and Karakoç., 2025; Wu et al., 2022).
Acupressure is a complementary treatment method that aims to control symptoms by applying pressure to specific points on the meridians (İskender and Çalışkan, 2020). During the application, sensitive pressure is applied to specific points on the body using the hands and fingers, and in some cases, special tools; this aims to regulate energy flow and support the body's natural healing processes (Dincer et al., 2022; Harris et al., 2020). These stimuli, applied through touch, can activate receptors in the skin of infants with HB and be transmitted to the brain centers via reflex pathways. This can stimulate the parasympathetic nervous system and the vagus nerve, accelerating bowel movements, contributing to the regulation of the digestive system, and helping to expel meconium more quickly (Roth and Sullivan, 2006). In this regard, it is crucial to correctly identify the appropriate acupressure points during the treatment process (Bayraktar, 2023).
The application of acupressure has been used in various clinical settings in the neonatal and pediatric populations, and its effects on different physiological outcomes have been investigated. The effects of acupressure on pain (Altıntaş, 2023; Oğul, 2023; Özkan and Balcı, 2018), infantile colic (Özgören, 2021), and chemotherapy-induced nausea and vomiting (Balcı, 2018) in the pediatric group have been examined in various studies. However, it has been determined that studies evaluating the effect of acupressure on HB in newborns (Wu et al., 2022) are quite limited. Therefore, the aim of this study is to evaluate the effect of acupressure applied to newborns on HB. In this context, the potential contributions of acupressure to reducing serum bilirubin levels and supporting the treatment process will be examined, and it is aimed that the findings will provide scientific evidence regarding the effectiveness of acupressure as a complementary approach in the management of hyperbilirubinemia and guide clinical practice.
- Conditions
- Hyperbilirubinemia
- Being tested
- Acupressure
- Medical subject headings
- Hyperbilirubinemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AcupressureBehavioural
Acupressure intervention
| Study group | Role | What they receive |
|---|---|---|
| Acupressure Group | Experimental | Newborns assigned to the intervention group receive standard acupressure at predetermined acupuncture points (ST36 - Zusanli and KI1 - Yongquan) by a trained practitioner 0 and 12 hours after birth. Each session lasts approximately 4 minutes. Total serum bilirubin levels are measured 24 hours after birth. All newborns continue to receive routine newborn care and feeding according to the unit protocol. Receives: Behavioral: Acupressure |
| Control Group | No intervention | Newborns assigned to the control group receive routine neonatal care and feeding according to unit protocol without any acupressure intervention. Total serum bilirubin levels are measured at the 24th hour of life. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total Serum Bilirubin Level
Measurement of total serum bilirubin level to evaluate the effect of acupressure on neonatal hyperbilirubinemia.
Measured: 24 hours after birth
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2026
- Study start5 May 2025
- Primary completion5 Feb 2026
- Study completion15 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HyperbilirubinemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yuzuncu Yil University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Veysel Can, Yuzuncu Yil University
- Investigators
- Veysel CAN, MD, PhD, Principal investigator, Yuzuncu Yil University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07409194
- Sponsor's protocol ID
- 2025/05-14
- Status last verified
- Oct 2026
- First submitted
- 6 Feb 2026
- Last updated
- 27 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Acupressure on Hyperbilirubinemia in Newborns: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07409194
- Acronym / sponsor ID
- 2025/05-14
- Conditions
- Hyperbilirubinemia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Yuzuncu Yil UniversityUniversity, hospital or other
- Study start
- 5 May 2025 (actual)
- Primary completion
- 5 Feb 2026 (actual)
- Study completion
- 15 May 2026 (actual)
- First posted
- 13 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a randomized controlled trial conducted to evaluate the effect of acupressure application on hyperbilirubinemia in newborns. The study examined the effect of regular acupressure applications to specific points on serum bilirubin levels in newborns at risk of developing physiological jaundice in the first days of life. By comparing bilirubin levels between the experimental and control groups, the potential benefits of acupressure in reducing the severity of jaundice and supporting bilirubin metabolism were investigated. The findings suggest that acupressure can be used as a complementary method in neonatal care.
Detailed description
One of the most common problems encountered in the neonatal period is neonatal jaundice, which develops due to an increase in indirect bilirubin (Özdemir and Yılmaz, 2019). Jaundice (hyperbilirubinemia) is defined as the yellowing of the skin and the whites of the eyes due to the accumulation of bilirubin in the skin and mucous membranes of newborns (Kılıç and Yılmaz, 2021). Jaundice is a common condition seen in 60% of term infants and more than 80% of preterm infants (Muniyappa and Kelley, 2020). Hyperbilirubinemia (HB), which is frequently seen in newborns, especially in the indirect form, is a mild health problem in most cases (Olcar, 2019; Yılmaz, 2019). HB in newborns usually progresses cephalocaudally (from head to toe); it starts in the face and spreads to the body as serum bilirubin levels increase (Turkish Neonatology Association [TND], 2022). Symptoms such as lethargy and feeding difficulties may occur in infants with severe HB. If not treated promptly, serious neurological complications such as kernicterus may occur. Early diagnosis, close monitoring, and treatment are vital to prevent potential damage in newborns (Muniyappa and Kelley, 2020).
Various treatment methods have been developed to reduce bilirubin levels. Among these methods, the most commonly used are blood exchange, phototherapy, and drug treatments (Garg et al., 2019; Kılıç and Yılmaz, 2021). To support neonatal HB treatment, studies evaluating the effectiveness of non-pharmacological and complementary applications, in addition to pharmacological methods, have also been conducted (Öztürk, 2025; Coşkun and Karakoç., 2025; Wu et al., 2022).
Acupressure is a complementary treatment method that aims to control symptoms by applying pressure to specific points on the meridians (İskender and Çalışkan, 2020). During the application, sensitive pressure is applied to specific points on the body using the hands and fingers, and in some cases, special tools; this aims to regulate energy flow and support the body's natural healing processes (Dincer et al., 2022; Harris et al., 2020). These stimuli, applied through touch, can activate receptors in the skin of infants with HB and be transmitted to the brain centers via reflex pathways. This can stimulate the parasympathetic nervous system and the vagus nerve, accelerating bowel movements, contributing to the regulation of the digestive system, and helping to expel meconium more quickly (Roth and Sullivan, 2006). In this regard, it is crucial to correctly identify the appropriate acupressure points during the treatment process (Bayraktar, 2023).
The application of acupressure has been used in various clinical settings in the neonatal and pediatric populations, and its effects on different physiological outcomes have been investigated. The effects of acupressure on pain (Altıntaş, 2023; Oğul, 2023; Özkan and Balcı, 2018), infantile colic (Özgören, 2021), and chemotherapy-induced nausea and vomiting (Balcı, 2018) in the pediatric group have been examined in various studies. However, it has been determined that studies evaluating the effect of acupressure on HB in newborns (Wu et al., 2022) are quite limited. Therefore, the aim of this study is to evaluate the effect of acupressure applied to newborns on HB. In this context, the potential contributions of acupressure to reducing serum bilirubin levels and supporting the treatment process will be examined, and it is aimed that the findings will provide scientific evidence regarding the effectiveness of acupressure as a complementary approach in the management of hyperbilirubinemia and guide clinical practice.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Acupressure Group | Experimental | Behavioral: AcupressureNewborns assigned to the intervention group receive standard acupressure at predetermined acupuncture points (ST36 - Zusanli and KI1 - Yongquan) by a trained practitioner 0 and 12 hours after birth. Each session lasts approximately 4 minutes. Total serum bilirubin levels are measured 24 hours after birth. All newborns continue to receive routine newborn care and feeding according to the unit protocol. |
| Control Group | No intervention | –Newborns assigned to the control group receive routine neonatal care and feeding according to unit protocol without any acupressure intervention. Total serum bilirubin levels are measured at the 24th hour of life. |
Who may qualify
- Ages
- 38 weeks to 42 months
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Gestational age ≥38 weeks
- Diagnosed with neonatal hyperbilirubinemia
- Hospitalized in the neonatal unit for at least 24 hours
- Birth weight ≥2500 g
- Written informed consent obtained from parents
Key exclusion criteria (5 listed)
- Preterm newborns
- Congenital metabolic disease or congenital anomalies
- Hemodynamically unstable newborns
- Newborns whose parents did not provide consent
- Newborns with any condition preventing acupressure application
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AcupressureAcupressure intervention | Behavioural | Acupressure Group |
Primary outcome
Total Serum Bilirubin Level
Time frame: 24 hours after birth
Measurement of total serum bilirubin level to evaluate the effect of acupressure on neonatal hyperbilirubinemia.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Hyperbilirubinemia
Active, not recruitingPhase 1/2
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
End-stage Liver Disease (ESLD), Cirrhosis, Liver
Recruiting
Abdominal Massage for Newborn Jaundice
Neonatal Jaundice
Recruiting
Foot Reflexology and Massage in Neonates Receiving Phototherapy
Neonatal Hyperbilirubinemia
Not yet recruiting
Supraglottic Oxygenation Via Oral Transtracheal Catheter for Reducing the Incidence of Hypoxemia During ERCP Under Sedation
Choledocholithiasis With Cholecystitis With Obstruction, Obstructive Jaundice
Active, not recruiting
Paternal Involvement in Nursing Guidance and Breastfeeding Self-Efficacy in Mothers of High-Risk Newborns
Prematurity, Low Birth Weight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Veysel CAN, MD, PhD principal investigator
Yuzuncu Yil University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Acupressure in people with Hyperbilirubinemia, run by Yuzuncu Yil University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total Serum Bilirubin Level (time frame: 24 hours after birth). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.